主要办公地址Lilly Corporate Center, Indianapolis, Indiana 46285 主要股东4 序号名称持股量(股)持股比例 1Lilly Endowment Inc.9689.2万10.21% 2The Vanguard Group7160.47万7.54% 3BlackRock, Inc.6437.6万6.78% 4The PNC Financial Services Group, Inc.5121.26万5.39% ...
In October 2006, Lilly announced its intention to acquire Icos for $2.1 billion, or $32 per share. In 2006, Gemzar® was approved for use in the treatment of women living with recurrent ovarian cancer. 2007 Institutional Shareholder Services (ISS), a proxy advisory firm, advised Icos share...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. That performance was in contrast to the S&P 500's (SNPINDEX: ^GSP
Eli Lilly didn't have a bad quarter, but when perfection is priced into a stock, anything less than glorious results can end up weighing on its valuation. And while the company's revenue rose by 20% to $11.4 billion for the third quarter ending Sept. 30, that fell short of analyst ex...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.
Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster diabetes and obesity care medications, Mounjaro and Zepboun
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, (NYSE: NVO) and it isn
For a top drugmaker like Eli Lilly (NYSE: LLY), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the h
Stock of Eli Lilly (NYSE: LLY), the famed Indianapolis pharmaceuticals giant, jumped 8.3% through 12:45 p.m. ET after the company reported a massive earnings beat this morning.